Tscan Therapeutics Inc 's ROA from the second quarter of 2026 to the second quarter of 2025 and 5 Year Period

Return on Assets, Quarterly Results, Trends, Rankings, Statistics

What is Tscan Therapeutics Inc 's ROA in the second quarter of 2026?
Tscan Therapeutics Inc recorded a cumulative net loss of $-118 million during 12 months ending in the second quarter of 2026, resulting in a negative return on assets (ROA) of -54.47%.

However, within the Healthcare sector 580 other companies had a higher return on assets. While Return on assets, overall ranking has advanced in the Jun 30 2026 quarter, so far to 3926, from total ROA ranking in the first quarter of 2026 at 4553.

What is ROA?

Select the Comparisons :

None ▼

Select the Ratio:

Return on Assets ROA▼

None ▼

Return on Assets ROA▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

Return On Assets	(Jun 30 2026) II. Quarter	(Mar 31 2026) I. Quarter	(Dec 31 2025) IV. Quarter	(Sep 30 2025) III. Quarter	(Jun 30 2025) II. Quarter
Y / Y Total Assets Change	-42.57 %	-39.29 %	-24.17 %	-7.46 %	-3.34 %
Y / Y Net Income Change	-	-	-	-	-
Net Income (TTM) in million	-118	-124	-130	-143	-137
Return On Assets (TTM)	-54.47 %	-50.14 %	-46.25 %	-47.72 %	-44.98 %
TCRX's Total Ranking	# 3926	# 4553	# 3974	# 3954	# 3969
Total Assets (TTM) in million	171	202	229	262	299
Seq. Total Assets Change	-15.12 %	-11.71 %	-12.75 %	-12.17 %	-10.26 %
Seq. Net Income Change	-	-	-	-	-

TCRX's 5 Years Annual ROA >> Back to TCRX Management Effectiveness >> Compare TCRX ROA to its Competitors

Return On Assets Company Ranking
Within:	No.
Industry	# 79
Sector	# 581
Overall	# 3935

Return On Assets Statistics
High	Average	Low
-9.35 %	-38.14 %	-54.47 %
(Mar 31 2022)		(Jun 30 2026)

Financial Statements
Tscan Therapeutics Inc 's Assets	$ 171 million	TCRX's Balance sheet
Tscan Therapeutics Inc 's Income	$ -30 million	Quarterly TCRX's Income Statement
TCRX's Income by Division		See TCRX's Income by Division

Annual Return On Assets	(Dec 31 2025) FY 2025	(Dec 31 2024) FY 2024	(Dec 31 2023) FY 2023	(Dec 31 2022) FY 2022	(Dec 31 2021) FY 2021
Y / Y Total Assets Change	-44.98 %	48.18 %	50.89 %	-24.01 %	-
Total Assets in million	166	302	204	135	178
Y / Y Net Income Change	-	-	-	-	-
Net Income in million	-130	-127	-89	-66	-49
Annual Return On Assets	-78.17 %	-42.26 %	-43.81 %	-49.07 %	-27.38 %

TCRX's 5 Years Annual ROA >> Back to TCRX Management Effectiveness >> Compare TCRX ROA to its Competitors

More Return On Assets Ratios
TCRX's' Return on Assets at Yahoo Finance
Biotechnology & Pharmaceuticals Industry Return On Assets Trends and Statistics
Healthcare Sector Roa Statistics
Roa Trends for overall market
TCRX's Roa Ratio versus Biotechnology & Pharmaceuticals Industry, Healthcare Sector and overall Market
Highest Ranking Return On Assets
Lowest Ranking Return On Assets
Subscribers only: Roa for TCRX's Competitors
Subscribers only: Roa for Tscan Therapeutics Inc 's Suppliers
Subscribers only: Return On Assets for TCRX's Customers

You may also want to know
TCRX's Roi	TCRX's Inventory Turnover Ratio	TCRX's Growth Rates	TCRX's Dividend Comparisons
	TCRX's Profitability Ratios	TCRX's Asset Turnover Ratio	TCRX's Dividend Growth
TCRX's Roe	TCRX's Valuation Ratios	TCRX's Financial Strength Ratios	TCRX's Dividend Payout Ratio

Companies with similar Return On Assets at Jun 30 2026, within Healthcare Sector

ROA

Date modified: 2026-09-12T06:25:36+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.